Oric Pharmaceuticals (ORIC) News Today $10.65 +0.51 (+5.03%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$10.79 +0.14 (+1.31%) As of 06:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Metastatic Prostate Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJuly 3 at 2:00 AM | theglobeandmail.comOric Pharmaceuticals (NASDAQ:ORIC) Trading 10% Higher - Time to Buy?July 2 at 5:47 PM | marketbeat.comOric Pharmaceuticals Inc. Advanced Charts | ORIC | Barron'sJune 28, 2025 | barrons.comOric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up After Insider Buying ActivityJune 26, 2025 | americanbankingnews.comOric Pharmaceuticals Shows Market Leadership With Jump To 93 RS RatingJune 25, 2025 | msn.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $10,340.00 in StockJune 25, 2025 | insidertrades.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 SharesJune 24, 2025 | marketbeat.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $340,893.00 in StockJune 24, 2025 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Insider Buying ActivityJune 24, 2025 | marketbeat.comAngie You Purchases 1,403 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) StockJune 24, 2025 | insidertrades.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 26,597 SharesJune 23, 2025 | marketbeat.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 1,403 SharesJune 23, 2025 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 6.2% - Here's What HappenedJune 23, 2025 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Receives Outperform Rating from WedbushJune 23, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Down 3.4% - Should You Sell?June 16, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down on Insider SellingJune 12, 2025 | marketbeat.comMillennium Management LLC Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)June 12, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 2,976 SharesJune 11, 2025 | marketbeat.comOric Pharmaceuticals files to sell 19.23M shares of common stock by selling shareholdersJune 11, 2025 | msn.comCantor Fitzgerald Weighs in on ORIC FY2026 EarningsJune 11, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Buy" from AnalystsJune 11, 2025 | marketbeat.comInsider Selling: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells 2,600 Shares of StockJune 10, 2025 | insidertrades.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $26,026.00 in StockJune 9, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Bank of America Corp DEJune 8, 2025 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?June 6, 2025 | marketbeat.comTwo Sigma Investments LP Decreases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)June 6, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Trading 7.6% Higher - Still a Buy?June 4, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.5% - Should You Sell?June 3, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume Increase - Time to Buy?June 3, 2025 | marketbeat.comResearch Analysts Set Expectations for ORIC FY2025 EarningsJune 2, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down - What's Next?May 31, 2025 | marketbeat.comORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for ...May 30, 2025 | morningstar.comMTraders Purchase High Volume of ORIC Pharmaceuticals Call Options (NASDAQ:ORIC)May 30, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)May 30, 2025 | marketbeat.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Should You Buy?May 30, 2025 | marketbeat.comOric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer TrialMay 29, 2025 | msn.comORIC Pharmaceuticals shares surge on promising trial dataMay 29, 2025 | in.investing.comORIC Pharmaceuticals Shares Rally 20% on Encouraging Cancer Drug Trial and Funding UpdateMay 29, 2025 | msn.comORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises CapitalMay 29, 2025 | benzinga.comORIC® Pharmaceuticals Announces $125 Million Private Placement FinancingMay 29, 2025 | tmcnet.comOric Pharma Shares Rise 18% on Cancer Drug Results, Private Placement NewsMay 29, 2025 | marketwatch.comORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 TrialsMay 28, 2025 | insidermonkey.comORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPCMay 28, 2025 | globenewswire.comORIC® Pharmaceuticals Announces $125 Million Private Placement FinancingMay 28, 2025 | globenewswire.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPCMay 27, 2025 | globenewswire.comFrazier Life Sciences Management L.P. Sells 254,617 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)May 23, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on ORIC sharesMay 22, 2025 | uk.investing.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by BrokeragesMay 19, 2025 | marketbeat.com Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Media Mentions By Week ORIC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼0.990.90▲Average Medical News Sentiment ORIC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼34▲ORIC Articles Average Week Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avidity Biosciences News Today Ultragenyx Pharmaceutical News Today Protagonist Therapeutics News Today Ascentage Pharma Group International News Today Scholar Rock News Today MoonLake Immunotherapeutics News Today Metsera News Today Viking Therapeutics News Today Kymera Therapeutics News Today MorphoSys News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORIC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.